Thus, we performed such an analysis for the first time, by investigating the expression of a broad panel of markers (CD22, CD25, CD30, CD33, CD123, and FcεRI) that have been reported to be expressed on clonal BMMC from SM patients. This evidence concerns the gene CD33 and systemic mastocytosis.